Oxidative and antioxidative status after anthracycline-based chemotherapy in breast cancer patients

被引:1
|
作者
Alacacioglu, A. [1 ]
Kebapcilar, L. [2 ]
Pamuk, B. Onder [2 ]
Sop, G. [2 ]
Kucukiravul, C. [2 ]
Bozkaya, G. [3 ]
Yuksel, A. [2 ]
Alacacioglu, I. [4 ]
Sari, I. [2 ]
机构
[1] Bozyaka Res & Training Hosp, Dept Med Oncol, TR-35360 Izmir, Turkey
[2] Bozyaka Res & Training Hosp, Dept Internal Med, TR-35360 Izmir, Turkey
[3] Bozyaka Res & Training Hosp, Dept Biochem, TR-35360 Izmir, Turkey
[4] Ataturk Training & Res Hosp, Dept Hematol, Izmir, Turkey
来源
JOURNAL OF BUON | 2013年 / 18卷 / 03期
关键词
anthracycline; breast cancer; SOD; TBARS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The present study was undertaken to evaluate the effects of adjuvant anthracycline-based chemotherapy on thiobarbituric acid reactive substances (TBARS) and superoxide dismutase (SOD) levels in patients with breast cancer who had undergone surgery. Methods: Body mass index (BMI), serum lipids (total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides), serum TBARS and SOD values were assessed in 30 patients with stage III breast cancer receiving adjuvant anthracydine-based chemotherapy. Results: Anthracycline-based chemotherapy had no effect on BMI, blood pressure and lipid profile. A significant elevation was noted in TBARS (5.5 +/- 0.6 vs 5.9 +/- 0.9}anon; p=0.038) and a significant reduction to baseline values in SOD levels (226.5 +/- 61.0 vs 203.1 +/- 48.3 U/mL; p=0.037) in patients following 6 cycles of adjuvant chemotherapy. Conclusion: The TBARS levels increased, whereas the SOD levels descreased after anthracycline-based chemotherapy. We suggest that oxidative stress is not always detrimental, as it can be beneficial in cancer treatment.
引用
收藏
页码:614 / 618
页数:5
相关论文
共 50 条
  • [41] Associations of MYC protein expression and gene status with breast cancer subtypes and outcome in patients treated with anthracycline-based adjuvant chemotherapy
    Batistatou, A.
    Razis, E.
    Bobos, M.
    Tsolaki, E.
    Timotheadou, E.
    Alexopoulou, Z.
    Goussia, A.
    Gogas, H.
    Koutras, A.
    Karina, M.
    Pentheroudakis, G.
    Efstratiou, I.
    Petraki, K.
    Sotiropoulou, M.
    Pavlakis, K.
    Koletsa, T.
    Kotoula, V.
    Fountzilas, G.
    CANCER RESEARCH, 2016, 76
  • [42] Effective Antiemetic Therapy Is Important With Adjuvant Anthracycline-based Chemotherapy in Breast Cancer
    Takala, Laura
    Barlund, Maarit
    Kellokumpu-Lehtinen, Pirkko-Liisa
    Pirkko, Liisa
    ANTICANCER RESEARCH, 2019, 39 (01) : 279 - 283
  • [43] The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer
    Kota K.J.
    Brufsky A.M.
    Current Breast Cancer Reports, 2017, 9 (4) : 210 - 216
  • [44] HER2 and response to anthracycline-based neoadjuvant chemotherapy in breast cancer
    Yao, L.
    Liu, Y.
    Li, Z.
    Ouyang, T.
    Li, J.
    Wang, T.
    Fan, Z.
    Fan, T.
    Lin, B.
    Xie, Y.
    ANNALS OF ONCOLOGY, 2011, 22 (06) : 1326 - 1331
  • [45] Anthracycline-based Chemotherapy in A Patient with Breast Cancer and Left-Ventricular Hypertrabeculation
    Rahme, Serena Joseph
    Cathcart-Rake, Elizabeth
    Giudicessi, John
    Giudicessi, John
    Herrmann, Joerg
    CIRCULATION, 2024, 150
  • [46] ANTHRACYCLINE-BASED CHEMOTHERAPY FOR BREAST CANCER - PREDICTIVE FACTORS OF DOSE INTENSITY REDUCTION
    Faustino, C.
    Afonso, N.
    Sousa, B.
    Rodrigues, H.
    ANNALS OF ONCOLOGY, 2008, 19 : 82 - 82
  • [47] Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
    Naomi B. Boekel
    Judy N. Jacobse
    Michael Schaapveld
    Maartje J. Hooning
    Jourik A. Gietema
    Frances K. Duane
    Carolyn W. Taylor
    Sarah C. Darby
    Michael Hauptmann
    Caroline M. Seynaeve
    Margreet H. A. Baaijens
    Gabe S. Sonke
    Emiel J. T. Rutgers
    Nicola S. Russell
    Berthe M. P. Aleman
    Flora E. van Leeuwen
    British Journal of Cancer, 2018, 119 : 408 - 418
  • [48] Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    Bertucci, Francois
    Borie, Nathalie
    Roche, Henri
    Bachelot, Thomas
    Le Doussal, Jean-Marc
    Macgrogan, Gaetan
    Debono, Stephane
    Martinec, Agnes
    Treilleux, Isabelle
    Finetti, Pascal
    Esterni, Benjamin
    Extra, Jean-Marc
    Geneve, Jean
    Hermitte, Fabienne
    Chabannon, Christian
    Jacquemier, Jocelyne
    Martin, Anne-Laure
    Longy, Michel
    Maraninchi, Dominique
    Fert, Vincent
    Birnbaum, Daniel
    Viens, Patrice
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 127 (02) : 363 - 373
  • [49] Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer
    Boekel, Naomi B.
    Jacobse, Judy N.
    Schaapveld, Michael
    Hooning, Maartje J.
    Gietema, Jourik A.
    Duane, Frances K.
    Taylor, Carolyn W.
    Darby, Sarah C.
    Hauptmann, Michael
    Seynaeve, Caroline M.
    Baaijens, Margreet H. A.
    Sonke, Gabe S.
    Rutgers, Emiel J. T.
    Russell, Nicola S.
    Aleman, Berthe M. P.
    van Leeuwen, Flora E.
    BRITISH JOURNAL OF CANCER, 2018, 119 (04) : 408 - 418
  • [50] Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer
    François Bertucci
    Nathalie Borie
    Henri Roche
    Thomas Bachelot
    Jean-Marc Le Doussal
    Gaëtan Macgrogan
    Stéphane Debono
    Agnès Martinec
    Isabelle Treilleux
    Pascal Finetti
    Benjamin Esterni
    Jean-Marc Extra
    Jean Geneve
    Fabienne Hermitte
    Christian Chabannon
    Jocelyne Jacquemier
    Anne-Laure Martin
    Michel Longy
    Dominique Maraninchi
    Vincent Fert
    Daniel Birnbaum
    Patrice Viens
    Breast Cancer Research and Treatment, 2011, 127 : 363 - 373